EE274 Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy

Abstract

To estimate the costs of grade 3/4 adverse events (AEs) related to amivantamab or mobocertinib among patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor exon 20 insertion mutation with disease progression despite prior platinum-based chemotherapy, from a Commercial or Medicare payer perspective.